Caren Deardorf, MBA

Board Member

Caren Deardorf is currently the chief commercial officer of Magenta Therapeutics, Inc., where she is responsible for the strategy, direction and execution of Magenta’s global commercial capabilities. Earlier in her career, Ms. Deardorf was chief commercial officer of Ohana Biosciences and VP of global product development at Biogen, where she was the commercial lead on Spinraza®, a treatment for children and adults with spinal muscular atrophy, a genetic disease affecting muscle strength and movement. At Biogen, she led disease awareness efforts for the first drug approved to treat SMA, a rare and often fatal inherited disease that typically presents in infancy. Earlier in her career at Biogen, Ms. Deardorf was responsible for brand and launch strategy for Tecfidera, a treatment for relapsing forms of multiple sclerosis. Ms. Deardorf earned a Bachelor of Science degree in biology at Tufts University and a Master of Business Administration from Olin Graduate School of Business at Babson College.